Nemolizumab Therapeutic Cheat Sheet
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a …
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a … 
Pigmentary distress impacts people of all skin types, according to Dr. Gilly Munavalli, associate clinical professor of dermatology at Wake Forest University School of Medicine. In an interview with Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, Dr. Munavalli shares how to use lasers and energy-based devices to treat pigmentary disorders. Find out what Dr. Munaval … 